About: Walter N. Kernan

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Walter N. Kernan Goto Sponge Distinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

Attributes	Values
rdf:type	Item
field of work	wds:Q112534137-07A96C6C-955A-4925-B4EA-D34100E28ABC wds:Q112534137-335D3D4C-6BAF-4AB9-9384-58C654310ED5
field of work	medicine internal medicine
description	lékař, univerzitní profesor; internista, věnuje se také problematice cévních mozkových příhod (cs)
rdfs:label	Walter N. Kernan (cs) Walter N. Kernan (en) Walter N. Kernan (sk) Walter N. Kernan (tr)
skos:prefLabel	Walter N. Kernan (cs) Walter N. Kernan (en) Walter N. Kernan (sk) Walter N. Kernan (tr)
name	Walter N. Kernan (cs) Walter N. Kernan (en) Walter N. Kernan (sk) Walter N. Kernan (tr)
given name	wds:Q112534137-13E0D7EE-3475-40F6-B7E5-576A4DDA27D7
given name	Walter
instance of	wds:Q112534137-C6FD0D86-E9FD-4997-A9FD-8AE8A48EB908
NL CR AUT ID	wds:Q112534137-5FB6CCD0-D068-4A72-857A-A5F84227256F
instance of	Homo sapiens
NL CR AUT ID	xx0234360
occupation	wds:Q112534137-3E8E4FF1-4297-4E05-AE9B-FA639854A885 wds:Q112534137-93193BA7-A489-41A1-86BF-69A27C7E0A3D
languages spoken, written or signed	wds:Q112534137-734BF9C5-4E07-43A0-9385-AB6019EEDD02
place of birth	wds:Q112534137-0EC265B3-0DB9-41D0-A640-A45CCBB5B529
sex or gender	wds:Q112534137-68A61424-8F0D-46B2-AEB7-C8DC45E562E3
VIAF ID	wds:Q112534137-195CCA6E-572A-4565-84C2-ADDA41C4A19A
date of birth	wds:Q112534137-DEC79A3C-3928-43FB-B7C5-C1BB9AB78778
family name	wds:Q112534137-C95A612F-2EE7-4CD1-A3D1-6384125E666F
VIAF ID	http://viaf.org/viaf/47155563962313000312
occupation	internist physician
languages spoken, written or signed	English
place of birth	Boston
sex or gender	male
VIAF ID	47155563962313000312
date of birth	1956-01-01 00:00:00Z (xsd:dateTime)
family name	Kernan
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q112534137
is author of	Pioglitazone after Ischemic Stroke or Transient Ischemic Attack Estrogen therapy and risk of cognitive decline: results from the Women's Estrogen for Stroke Trial (WEST). Prevalence of abnormal glucose tolerance following a transient ischemic attack or ischemic stroke Altruism as a reason for participation in clinical trials was independently associated with adherence Pioglitazone for secondary prevention after ischemic stroke and transient ischemic attack: rationale and design of the Insulin Resistance Intervention after Stroke Trial Major risk factors for intracerebral hemorrhage in the young are modifiable Pioglitazone improves insulin sensitivity among nondiabetic patients with a recent transient ischemic attack or ischemic stroke Major risk factors for aneurysmal subarachnoid hemorrhage in the young are modifiable Adherence reporting in randomized controlled trials Smoking cessation and outcome after ischemic stroke or TIA. Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack: Effects of Pioglitazone in Patients With Insulin Resistance Without Diabetes Mellitus Decline in physical performance among women with a recent transient ischemic attack or ischemic stroke: opportunities for functional preservation a report of the Women's Estrogen Stroke Trial. Influence of race, clinical, and other socio-demographic features on trial participation. Targeting Pioglitazone Hydrochloride Therapy After Stroke or Transient Ischemic Attack According to Pretreatment Risk for Stroke or Myocardial Infarction. Scoring System to Optimize Pioglitazone Therapy After Stroke Based on Fracture Risk Pioglitazone and Risk for Bone Fracture: Safety Data From a Randomized Clinical Trial A Diagnostic Score for Insulin Resistance in Nondiabetic Patients with Ischemic Stroke or Transient Ischemic Attack Pioglitazone Therapy in Patients With Stroke and Prediabetes: A Post Hoc Analysis of the IRIS Randomized Clinical Trial Heart Failure After Ischemic Stroke or Transient Ischemic Attack in Insulin-Resistant Patients Without Diabetes Mellitus Treated With Pioglitazone Litigation seeking access to data from ongoing clinical trials: a threat to clinical research Disagreement between students and preceptors regarding the value of teaching behaviors for ambulatory care settings. Metabolic rehabilitation: science gathers to support a new intervention to prevent stroke Clinical assessment of function among women with a recent cerebrovascular event: a self-reported versus performance-based measure Pioglitazone Prevents Stroke in Patients With a Recent Transient Ischemic Attack or Ischemic Stroke: A Planned Secondary Analysis of the IRIS Trial (Insulin Resistance Intervention After Stroke). Distance from Home to Research Center: A Barrier to In-Person Visits but Not Treatment Adherence in a Stroke Trial. Achievement of Guideline-Recommended Weight Loss Among Patients With Ischemic Stroke and Obesity Diabetes prevention and cardiovascular complications Taking care of volunteers in a stroke trial: a new assisted-management strategy Response by Young et al to Letters Regarding Article, "Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack: Effects of Pioglitazone in Patients With Insulin Resistance Without Diabetes Mellitus". Effects of pioglitazone on cognitive function in patients with a recent ischaemic stroke or TIA: a report from the IRIS trial An Error in An Old Paper Illustrates the Need for Data/Code Archives - Author response Metabolic syndrome identifies normal weight insulin-resistant stroke patients at risk for recurrent vascular disease
is author of	wds:Q34625239-CBC76DAF-FB56-4DE3-93BA-176F87D4BBAC wds:Q48569413-0B403012-1B8F-4A15-8CC5-97A9A998B5C4 wds:Q49105239-95CB0C20-CD41-4008-B7FA-008CA111EED4 wds:Q43750292-73CD13D9-D02E-414C-AE48-003318F68BE8 wds:Q47886343-BDC5B27A-2CDD-41F8-807D-E3EF1316F3A5 wds:Q30837735-13415006-483E-49A8-BABB-BE3D5980069E wds:Q35580956-094A0837-2454-4DCE-A70C-38CB7BFC62DA wds:Q38380127-3B9345C8-B50E-443E-83B1-D9459E05759F wds:Q46636014-5E8949AC-ABB7-4DD4-99EB-42E2B282A8CB wds:Q44580066-785344CE-4D65-47C0-B0BC-7BCA5909A5FC wds:Q81348901-DDA19DC0-59BC-45FA-B74E-E6F8FFDB698D wds:Q91755251-67221997-F349-45CA-BB42-460FC4CAA534 wds:Q45254285-3EA9EB8E-193F-4718-9C71-098C78B043DF wds:Q64969478-73540A62-37EA-4DEA-9B38-AB6EE8F5AF91 wds:Q90111393-6520DFC4-BD4A-462C-8FFF-283BDB1FA397 wds:Q36217472-567695BA-DAA1-4173-8ABD-AA12F784AF55 wds:Q41678642-04A49348-B083-4C07-8BD1-65474BD7923A wds:Q45939225-A602CEB9-8B9A-4E5F-8446-046216881604 wds:Q50077234-6846650E-8E93-4432-9DD0-2F27B9E14211 wds:Q38172903-F06FC2CB-B1AE-4497-9AE4-0BBEAED547CD wds:Q41995051-248A09C4-9B8A-48CB-9DEF-EE94E7C2D18F wds:Q44429526-16A6EACB-85BF-4803-ABC9-9087C983BD56 wds:Q50223759-0E0935F2-6E9F-42E6-9386-4619D2038D2E wds:Q89206583-B14D67C4-2ED0-4322-9CD0-1C9C1EF2334C wds:Q36953272-E5D278D9-C0F8-4A85-B29D-771F92E0F48F

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 180 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software